3,053 results match your criteria non-muscle invasive

Narrative review: update on immunotherapy and pathological features in patients with bladder cancer.

Transl Androl Urol 2021 Mar;10(3):1521-1529

Section of Pathological Anatomy, United Hospitals, School of Medicine, Polytechnic University of the Marche Region, Ancona, Italy.

Over the last few years efficacy of immunotherapy using immune checkpoint inhibitors (ICI) has been investigated in patients with bladder cancer (BC) at all stages. The present article aims to assess new therapeutic options with emerging agents in BC patients, shedding light on ICI-based treatments encompassing all disease stages, from non-muscle invasive (NMIBC) to muscle-invasive (MIBC) BC, concluding with metastatic MIBC. In bacillus Calmette-Guerin (BCG) unresponsive patients with carcinoma in situ, pembrolizumab has been recently approved. Read More

View Article and Full-Text PDF

Targeted deep sequencing of bladder tumors reveals novel associations between cancer gene mutations and mutational signatures with major risk factors.

Clin Cancer Res 2021 Apr 13. Epub 2021 Apr 13.


Purpose: Exome and whole-genome sequencing of muscle-invasive bladder cancer (BC) has revealed important insights into the molecular landscape; however, there are few studies of non-muscle invasive BC with detailed risk factor information.

Experimental Design: We examined the relationship between smoking and other BC risk factors and somatic mutations and mutational signatures in bladder tumors. Targeted sequencing of frequently mutated genes in BC was conducted in 322 formalin-fixed paraffin-embedded bladder tumors from a population-based case-control study. Read More

View Article and Full-Text PDF

Systematic review and meta-analysis of radiation therapy for high-risk non-muscle invasive bladder cancer.

Urol Oncol 2021 Apr 10. Epub 2021 Apr 10.

University of Colorado, Division of Urology, Aurora, CO; Yale University, Cancer Outcomes and Public Policy Effectiveness Research, (COPPER) Center, New Haven, CT. Electronic address:

Introduction: Radiation therapy (XRT) has been investigated as a possible treatment for high-risk non-muscle invasive bladder cancer (NMIBC) with the goal of bladder preservation, especially with the ongoing Bacillus Calmette-Guerin (BCG) shortage. Yet, little is known about the clinical efficacy and the quality of evidence supporting XRT for NMIBC. Herein, we performed a systematic review and meta-analysis to evaluate XRT in the treatment of patients with high-risk NMIBC. Read More

View Article and Full-Text PDF

Lymphocyte-to-Monocyte Ratio Is the Independent Prognostic Marker of Progression in Patients Undergoing BCG-Immunotherapy for Bladder Cancer.

Front Oncol 2021 26;11:655000. Epub 2021 Mar 26.

Department of Urology, Medical University of Silesia, Zabrze, Poland.

Introduction: Transurethral resection of bladder tumor with subsequent BCG immunotherapy is the current gold standard in the treatment of high risk and some medium-risk non-muscle invasive bladder cancer. Clinical factors like stage, grade, age and gender are well-know predictors of progression to muscle-invasive bladder cancer. In recent years novel hematological biomarkers were shown to be independent predictors of progression. Read More

View Article and Full-Text PDF

Holmium LASER in Comparison with Transurethral Resection of the Bladder Tumor for Non-muscle Invasive Bladder Cancer: Randomized Clinical Trial with 18-month Follow-up.

Urol J 2021 Apr 11. Epub 2021 Apr 11.

LASER Application in Medical Sciences Research Center (LAMSRC), Shahid Beheshti University of Medical Sciences.

Purpose: To evaluate the safety and efficacy of holmium LASER resection of the bladder tumor (HoLRBT) vs. transurethral resection of bladder tumor (TURBT) as the first treatment modality for non-muscle-invasive bladder cancer (NMIBC).

Materials And Methods: Eighty-eight patients with primary non-muscle invasive bladder cancer were allocated randomly in two groups who were treated with HoLRBT or TURBT. Read More

View Article and Full-Text PDF

Active surveillance for non-muscle invasive bladder cancer: A systematic review and pooled-analysis.

Cancer Treat Res Commun 2021 Apr 3;27:100369. Epub 2021 Apr 3.

IRCCS Humanitas Research Hospital - Rozzano, Milan, Italy.

Introduction: One of the Non-Muscle Invasive Bladder Cancer (NMIBC) treatment options recently recommended by International Guidelines is represented by Active Surveillance (AS),. Herein we carried out a systematic review and pooled-analysis of currently available evidences in order to provide recommendations for daily urological practice.

Material And Methods: The PubMed, EMBASE, and Coch rane Library databases were searched with the terms "Non-Muscle Invasive" or "pTa/pT1" and "Bladder Cancer" or "Bladder Tumor". Read More

View Article and Full-Text PDF

First time intravesically administered trifunctional antibody catumaxomab in patients with recurrent non-muscle invasive bladder cancer indicates high tolerability and local immunological activity.

Cancer Immunol Immunother 2021 Apr 10. Epub 2021 Apr 10.

Trion Research GmbH, Am Klopferspitz 19, 82152, Martinsried, Germany.

Transurethral resection of the tumor (TUR-B) followed by adjuvant intravesical treatment with cytostatic drugs or Bacillus Calmette-Guérin (BCG) as standard therapy of non-muscle-invasive bladder cancer (NMIBC) is associated with a high recurrence rate of about 60-70%, considerable side effects and requires close monitoring. Alternative treatment options are warranted. Two patients with epithelial cell adhesion molecule (EpCAM)-positive recurrent non-muscle invasive bladder cancer were treated the first time by an intravesical administration of the trifunctional bispecific EpCAM targeting antibody catumaxomab (total dosage of 470 and 1120 µg, respectively). Read More

View Article and Full-Text PDF

The Impact of Non-Compliance to a Standardized Risk-Adjusted Protocol on Recurrence, Progression, and Mortality in Non-Muscle Invasive Bladder Cancer.

Cancer Manag Res 2021 31;13:2937-2945. Epub 2021 Mar 31.

Bristol Urological Institute, North Bristol NHS Trust, Bristol, UK.

Purpose: Non-muscle invasive bladder cancer (NMIBC) is a potentially curable or controllable disease if strict adherence to a surveillance protocol is followed. Management and surveillance of NMIBC begins at the time of diagnosis up to a few years thereafter. There is scanty data in the literature evaluating the impact of non-compliance with the surveillance protocols on progression, recurrence, and mortality rate. Read More

View Article and Full-Text PDF

Assessing treatment response after intravesical bacillus Calmette-Guerin induction cycle: are routine bladder biopsies necessary?

World J Urol 2021 Apr 8. Epub 2021 Apr 8.

Department of Urology and Renal Transplantation, University of Foggia-Ospedali Riuniti of Foggia, Foggia, Italy.

Purpose: To determine the need for routine bladder biopsies (BBs) in assessing response to the induction cycle of intravesical bacillus Calmette-Guérin (BCG) for high-risk non-muscle-invasive bladder cancer (NMIBC).

Methods: Our prospectively maintained NMIBC database was queried to identify patients with high-risk disease (carcinoma in situ, high-grade Ta/T1) who underwent BBs after BCG induction cycle. Urine cytology, cystoscopy, and BBs findings were evaluated. Read More

View Article and Full-Text PDF

Proteomic comparison between different tissue preservation methods for identification of promising biomarkers of urothelial bladder cancer.

Sci Rep 2021 Apr 7;11(1):7595. Epub 2021 Apr 7.

Department of Chemistry-BMC, Analytical Chemistry, Uppsala University, Box 599, 751 24, Uppsala, Sweden.

Samples in biobanks are generally preserved by formalin-fixation and paraffin-embedding (FFPE) and/or optimal cutting temperature compound (OCT)-embedding and subsequently frozen. Mass spectrometry (MS)-based analysis of these samples is now available via developed protocols, however, the differences in results with respect to preservation methods needs further investigation. Here we use bladder urothelial carcinoma tissue of two different tumor stages (Ta/T1-non-muscle invasive bladder cancer (NMIBC), and T2/T3-muscle invasive bladder cancer (MIBC)) which, upon sampling, were divided and preserved by FFPE and OCT. Read More

View Article and Full-Text PDF

Imaging and Management of Bladder Cancer.

Cancers (Basel) 2021 Mar 19;13(6). Epub 2021 Mar 19.

Department of Abdominal Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Houston, TX 77030, USA.

Methods: Keyword searches of Medline, PubMed, and the Cochrane Library for manuscripts published in English, and searches of references cited in selected articles to identify additional relevant papers. Abstracts sponsored by various societies including the American Urological Association (AUA), European Association of Urology (EAU), and European Society for Medical Oncology (ESMO) were also searched.

Background: Bladder cancer is the sixth most common cancer in the United States, and one of the most expensive in terms of cancer care. Read More

View Article and Full-Text PDF

Detection of Urothelial Bladder Cancer Based on Urine and Tissue Telomerase Activity Measured by Novel RT-TRAP-2PCR Method.

J Clin Med 2021 Mar 4;10(5). Epub 2021 Mar 4.

Institute for Urology and Reproductive Health, Sechenov University, 119435 Moscow, Russia.

Purpose: To assess the diagnostic performance of urine telomerase activity (TA) in detecting bladder cancer (BCa) using the modified Telomeric Repeat Amplification Protocol (TRAP) and the Real Time Telomeric Repeat Amplification Protocol with double Polymerase Chain Reaction (RT-TRAP-2PCR).

Methods: In this case-control study, matching urine (in the pre- and post-surgical period) and tissue samples from 68 patients with BCa were assessed for TA. As a control, 45 urine samples were examined from non-BCa patients. Read More

View Article and Full-Text PDF

Imaging of Bladder Cancer: Standard Applications and Future Trends.

Medicina (Kaunas) 2021 Mar 1;57(3). Epub 2021 Mar 1.

Radiology Department, Urology and Nephrology Center, Mansoura University, Mansoura 35516, Egypt.

The evolution in imaging has had an increasing role in the diagnosis, staging and follow up of bladder cancer. Conventional cystoscopy is crucial in the diagnosis of bladder cancer. However, a cystoscopic procedure cannot always depict carcinoma in situ (CIS) or differentiate benign from malignant tumors prior to biopsy. Read More

View Article and Full-Text PDF

Improving Anti-PD-1/PD-L1 Therapy for Localized Bladder Cancer.

Int J Mol Sci 2021 Mar 10;22(6). Epub 2021 Mar 10.

Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA.

In high-risk non-muscle invasive bladder cancer (HR-NMIBC), patient outcome is negatively affected by lack of response to (BCG) treatment. Lack of response to cisplatin-based neoadjuvant chemotherapy and cisplatin ineligibility reduces successful treatment outcomes in muscle-invasive bladder cancer (MIBC) patients. The effectiveness of PD-1/PD-L1 immune checkpoint inhibitors (ICI) in metastatic disease has stimulated its evaluation as a treatment option in HR-NMIBC and MIBC patients. Read More

View Article and Full-Text PDF

Biomarker-Oriented Therapy in Bladder and Renal Cancer.

Int J Mol Sci 2021 Mar 11;22(6). Epub 2021 Mar 11.

Department of Urology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands.

Treatment of patients with urothelial carcinoma (UC) of the bladder or renal cancer has changed significantly during recent years and efforts towards biomarker-directed therapy are being investigated. Immune checkpoint inhibition (ICI) or fibroblast growth factor receptor (FGFR) directed therapy are being evaluated for non-muscle invasive bladder cancer (NMIBC) patients, as well as muscle-invasive bladder cancer (MIBC) patients. Meanwhile, efforts to predict tumor response to neoadjuvant chemotherapy (NAC) are still ongoing, and genomic biomarkers are being evaluated in prospective clinical trials. Read More

View Article and Full-Text PDF

Application of deep learning as a noninvasive tool to differentiate muscle-invasive bladder cancer and non-muscle-invasive bladder cancer with CT.

Eur J Radiol 2021 Mar 19;139:109666. Epub 2021 Mar 19.

Department of Biotherapy and Cancer Center, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Guoxue Road 37, Chengdu, 610041, China. Electronic address:

Objective: To construct a deep-learning convolution neural network (DL-CNN) system for the differentiation of muscle-invasive bladder cancer (MIBC) and non-muscle-invasive bladder cancer (NMIBC) on contrast-enhanced computed tomography (CT) images in patients with bladder cancer.

Materials And Methods: A total of 1200 cross-sectional CT images were obtained from 369 patients with bladder cancer receiving radical cystectomy from January 2015 to June 2018, including 249 non-muscle-invasive bladder cancer (NMIBC) series and 120 muscle-invasive bladder cancer (MIBC) series. All eligible images were distributed randomly into the training, validation, and testing cohorts with ratios of 70 %, 15 %, and 15 %, respectively. Read More

View Article and Full-Text PDF

Tumor Resection, Optical Molecular Imaging, and the Potential Synergy of the Combination of the Two Techniques in Bladder Cancer.

Front Oncol 2021 16;11:638083. Epub 2021 Mar 16.

First Clinical Medical College, Shanxi Medical University, Taiyuan, China.

Although transurethral resection of bladder tumor is the golden standard for the treatment of non-muscle invasive bladder cancer, this surgical procedure still has some serious drawbacks. For example, piecemeal resection of tumor tissue results in exfoliated tumor cells dissemination and implantation, and fragmented tumor specimens make it difficult for pathologists to accurately assess the pathological stage and histologic grade. En bloc tumor resection follows the basic principle of oncological surgery and provides an intact tumor specimen containing detrusor muscle for pathologists to make accurate histopathological assessment. Read More

View Article and Full-Text PDF

Longitudinal Follow-up and Performance Validation of a mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non-Muscle Invasive Bladder Cancer Patients.

BJU Int 2021 Apr 1. Epub 2021 Apr 1.

UT Southwestern, 5323 Harry Hines Blvd. J8.112, Dallas, TX, 75390-9110, USA.

Purpose: Frequent recurrences and the potential for progression of non-muscle-invasive bladder cancer (NMIBC) demand close surveillance. This prospective study evaluated the performance of Xpert Bladder Cancer Monitor (Xpert) test as a predictor of tumor recurrence.

Patients And Methods: Patients (n=429) undergoing surveillance for NMIBC underwent Xpert, cytology, and UroVysion testing. Read More

View Article and Full-Text PDF

Quantifying the Costs of Care Among Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated in the Veterans Health Administration.

JAMA Netw Open 2021 Mar 1;4(3):e213816. Epub 2021 Mar 1.

Division of Oncology, Department of Internal Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City.

View Article and Full-Text PDF

Estimated Costs and Long-term Outcomes of Patients With High-Risk Non-Muscle-Invasive Bladder Cancer Treated With Bacillus Calmette-Guérin in the Veterans Affairs Health System.

JAMA Netw Open 2021 Mar 1;4(3):e213800. Epub 2021 Mar 1.

Durham Veterans Affairs Health Care System, Durham, North Carolina.

Importance: Management of high-risk non-muscle-invasive bladder cancer (NMIBC) represents a clinical challenge due to high failure rates despite prior bacillus Calmette-Guérin (BCG) therapy.

Objective: To describe real-world patient characteristics, long-term outcomes, and the economic burden in a population with high-risk NMIBC treated with BCG therapy.

Design, Setting, And Participants: This retrospective cohort study identified 412 patients with high-risk NMIBC from 63 139 patients diagnosed with bladder cancer who received at least 1 dose of BCG within Department of Veterans Affairs (VA) centers across the US from January 1, 2000, to December 31, 2015. Read More

View Article and Full-Text PDF

Can repeat biopsy be skipped after initial complete resection of T1 bladder cancer? The role of a novel urinary mRNA biomarker.

Urol Oncol 2021 Mar 27. Epub 2021 Mar 27.

Urology and Nephrology Center, Mansoura University, Mansoura-Egypt.

Objectives: To prospectively investigate the role of a urinary mRNA biomarker (Xpert Test) after initial complete resection of T1 bladder cancer (BC) for the prediction of positive repeat biopsy for malignancy.

Methods: Patients who underwent TURBT for NMIBC between September 2018 and April 2020 were included. Patients with benign pathology, incomplete resection, concomitant CIS/upper tract urothelial tumor or muscle invasive BC, were excluded. Read More

View Article and Full-Text PDF

Protective role of intravesical BCG in COVID-19 severity.

BMC Urol 2021 Mar 30;21(1):50. Epub 2021 Mar 30.

Departamento de Urología, Facultad de Medicina, Pontificia Universidad Católica de Chile, Diagonal Paraguay 362, Santiago, Chile.

Objectives: To establish the role of BCG instillations in the incidence and mortality of COVID-19.

Patients And Methods: NMIBC patients in instillations with BCG (induction or maintenance) during 2019/2020 were included, establishing a COVID-19 group (with a diagnosis according to the national registry) and a control group (NO-COVID). The cumulative incidence (cases/total patients) and the case fatality rate (deaths/cases) were established, and compared with the national statistics for the same age group. Read More

View Article and Full-Text PDF

Comparison of Thulium Laser Resection of Bladder Tumors and Conventional Transurethral Resection of Bladder Tumors for Non-Muscle-Invasive Bladder Cancer.

Urol Int 2021 Mar 30:1-6. Epub 2021 Mar 30.

Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.

Introduction: The thulium laser resection of bladder tumors (TmLRBT) was increasingly used in the treatment of non-muscle-invasive bladder cancer (NMIBC) recently, and here we report the relevant outcomes of our institution to evaluate its efficacy and safety.

Methods: We retrospectively collected the data of NMIBC patients who underwent either TmLRBT or transurethral resection of bladder tumor (TURBT). The baseline characteristics and perioperative outcomes were compared in these 2 groups. Read More

View Article and Full-Text PDF

Time Interval from Transurethral Resection of Bladder Tumor to BCG Induction Does Not Impact Therapeutic Response.

BJU Int 2021 Mar 30. Epub 2021 Mar 30.

Department of Urology, University of Texas MD Anderson Cancer Center, Houston.

Objectives: To investigate BCG tolerability and response with respect to timing of BCG administration following TUR in patients with non-muscle invasive bladder cancer (NMIBC).

Patients And Methods: A review of NMIBC patients at our institution managed with at least 'adequate BCG' (defined by the US FDA as at least 5/6 induction instillations with 2 additional instillations comprising either maintenance or repeat induction) at our institution from 2000-2018 was performed. Time from TUR to first instillation of induction BCG was stratified by quartile and analyzed as a continuous variable. Read More

View Article and Full-Text PDF

Immune checkpoint inhibitors for BCG-resistant NMIBC: the dawn of a new era.

Minerva Urol Nephrol 2021 Mar 29. Epub 2021 Mar 29.

Urology Department, Sant'Andrea Hospital, Università degli Studi di Roma La Sapienza, Rome, Italy.

Introduction: High risk non-muscle invasive bladder cancer (NMIBC) is a recurring and potentially lethal disease. To date, with the exception of radical surgery, there are no validated strategies for patients not responding to intravesical BCG therapy. Immune Checkpoint Inhibitors (ICI) are currently being tested for BCG-resistant NMIBC. Read More

View Article and Full-Text PDF

Clinical Significance of Horizontal and Vertical Margin of En Bloc Resection for Non-Muscle Invasive Bladder Cancer.

J Urol 2021 Mar 29:101097JU0000000000001735. Epub 2021 Mar 29.

Department of Urology, The Jikei University School of Medicine, Kashiwa, Chiba, Japan.

Purpose: The primary advantage of en bloc resection of bladder tumors (ERBT) is to provide better diagnostic accuracy. However, the clinical significance of horizontal and vertical margin has not been demonstrated. We evaluated the clinical importance of surgical margins in patients who underwent ERBT. Read More

View Article and Full-Text PDF

Overnight Continuous Saline Bladder Irrigation After Resection of Bladder Tumor Does Not Improve Oncological Outcomes in Patients Who Have Received Intravesical Chemotherapy.

Front Oncol 2021 10;11:638065. Epub 2021 Mar 10.

First Clinical Medical College, Shanxi Medical University, Taiyuan, China.

Objective: To evaluate the safety and efficacy of overnight continuous saline bladder irrigation (CSBI) for patients who have received thulium laser resection of bladder tumor (TmLRBT) combined with immediate intravesical chemotherapy previously.

Methods: From October 2014 to June 2018, 235 patients with newly diagnosed non-muscle invasive bladder cancer (NMIBC) were included in this retrospective study. All patients received intravesical instillation of pirarubicin immediately after TmLRBT. Read More

View Article and Full-Text PDF